NCT06925737 2026-03-13
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
Clinical Trials
42 trialsNCT06136650 2026-03-09
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT02257736 2026-02-13
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT06470243 2026-01-22
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT05204927 2025-07-31
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Curium US LLC
Phase 3 Active not recruiting
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04100018 2025-06-12
CheckMate 7DX
Bristol-Myers Squibb
Phase 3 Completed
NCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT00887198 2025-02-04
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT01715285 2025-02-04
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Janssen Research & Development, LLC
Phase 3 Completed
NCT04907227 2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT04887506 2024-01-16
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
Phase 3 Completed
NCT01949337 2023-09-28
Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT00004124 2022-12-30
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
SWOG Cancer Research Network
Phase 3 Completed
NCT00288080 2022-06-21
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00134056 2021-10-27
S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT01591122 2020-01-21
Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT01695135 2019-07-18
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT01193257 2018-12-19
Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.
Takeda
Phase 3 Completed
NCT01522443 2018-05-23
COMET-2
Exelixis
Phase 3 Terminated
NCT00988208 2018-04-04
Mainsail
Celgene
Phase 3 Completed
NCT01193244 2017-05-17
Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 3 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT00744497 2016-10-17
READY
Bristol-Myers Squibb
Phase 3 Completed
NCT01188187 2016-10-14
SYNERGY
Achieve Life Sciences
Phase 3 Completed
NCT01578655 2016-10-12
AFFINITY
Achieve Life Sciences
Phase 3 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT00024167 2016-03-22
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00110214 2014-05-09
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 3 Completed
NCT00004001 2014-02-25
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy
SWOG Cancer Research Network
Phase 3 Completed
NCT00255606 2013-06-26
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00003343 2012-08-08
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
Pfizer
Phase 3 Completed
NCT00069745 2012-08-07
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
Agennix
Phase 3 Completed
NCT00436839 2012-07-09
Taxotere Prostate Cancer New Indication Registration Trial in China
Sanofi
Phase 3 Completed
NCT00705822 2010-11-30
PROSTATA
Sanofi
Phase 3 Terminated
NCT00089856 2008-11-05
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Cell Genesys
Phase 3 Terminated
NCT00133224 2008-09-23
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Cell Genesys
Phase 3 Terminated